On the heels of the FDA’s full approval of Biogen and Eisai’s Leqembi, AC Immune’s CEO is hopeful that a precision medicine approach with improved diagnosis, prevention and treatment of Alzheimer’s disease is not far down the road. With 16 clinical programs, notable partnerships and wholly owned assets, AC Immune holds a strong position to help reach that destination.

Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – featured here are big pharma and industry experts.

Mass screening of asymptomatic people is an expensive, daunting proposition, but very preliminary research with an amyloid beta blood test is spurring hope that a more practical way to identify those at risk will emerge in the future.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.